Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma

Targeting STARD4/EGFR axis inhibits growth and overcomes lenvatinib resistance in hepatocellular carcinoma

Lenvatinib is widely used as a first-line chemotherapy for advanced hepatocellular carcinoma (HCC), a highly metastatic and recurrent cancer. However, HCC cells often develop resistance to lenvatinib, thus reducing its efficacy. This study aims to investigate the impact of STARD4, a crucial choleste...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mengting Liu, Yixin Liu, Jiahui Zheng, Xiangping An, Jiayong Wen, Fengchi Zhu, Jin Jia, Dan Guo, Nana Chen
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2025-11-01
Series:	Genes and Diseases
Subjects:	EGFR/PI3K/AKT pathway Hepatocellular carcinoma Invasion Lenvatinib resistance Migration Proliferation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352304225000455
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Elevated SLC4A11 expression promotes OV progression via interaction with EGFR
by: Qihua Peng, et al.
Published: (2025-07-01)

FERMT1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by activating EGFR/AKT/β-catenin and EGFR/ERK pathways
by: Wubin Guo, et al.
Published: (2024-12-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer
by: T. A. Dronova, et al.
Published: (2018-11-01)

Lenvatinib promotes hepatocellular carcinoma pyroptosis by regulating GSDME palmitoylation
by: Yuan Yuan, et al.
Published: (2025-12-01)

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
by: Olivier Calvayrac, et al.
Published: (2016-12-01)

Pulmonary hemorrhage and hemopneumothorax following the administration of lenvatinib for lung metastasis from hepatocellular carcinoma
by: Kazuya Kishimoto, et al.
Published: (2025-01-01)

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
by: Young Eun Chon, et al.
Published: (2025-01-01)

Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications
by: Bixing Zhao, et al.
Published: (2025-05-01)

9th surgery decoction alleviates psoriasis-like inflammation through the downregulation of angiogenesis induced by HIF-1α and the EGFR-PI3K-AKT-mTOR pathways
by: Shengjie Zhu, et al.
Published: (2025-08-01)

CircRNA‐mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1/c‐Myc Axis
by: Yongchang Tang, et al.
Published: (2025-05-01)

Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report
by: Xiaoqing Li, et al.
Published: (2025-03-01)

Involvement of EGFR-AKT signaling in hemin-induced neurotoxicity
by: Hui-Ju Huang, et al.
Published: (2025-05-01)

Acute vascular and cardiac effects of lenvatinib in mice
by: Dustin N. Krüger, et al.
Published: (2025-02-01)

Adjuvant Lenvatinib for High-Risk CNLC IIb/IIIa Hepatocellular Carcinoma After Curative Hepatectomy: A Prospective Exploratory Study
by: Sun HC, et al.
Published: (2025-05-01)

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study
by: Jiajin Yang, et al.
Published: (2025-04-01)

Vortioxetine exhibits anti-glioblastoma activity via the PI3K-Akt signaling pathway
by: Huan-Qi Zhang, et al.
Published: (2025-04-01)

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
by: Yuki Ohya, et al.
Published: (2020-12-01)

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer
by: Lu Xia, et al.
Published: (2025-07-01)

Knockdown of PRR14 inhibits the growth and migration of gastric cancer cells
by: Maozhao Yan, et al.
Published: (2025-06-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Plinabulin exerts an anti-proliferative effect via the PI3K/AKT/mTOR signaling pathways in glioblastoma
by: Rouxin Wang, et al.
Published: (2025-01-01)

The Electric Field Guided HaCaT Cell Migration Through the EGFR/p38 MAPK/Akt Pathway
by: Huajian Zhou, et al.
Published: (2024-12-01)

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation
by: Kyunghye Bang, et al.
Published: (2023-02-01)

Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
by: JIANG Jiayun, et al.
Published: (2024-11-01)

Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib
by: Naoki Fukuda, et al.
Published: (2024-04-01)

Conversion surgery after lenvatinib treatment for anaplastic thyroid carcinoma: a case report
by: Haruhiko Yamazaki, et al.
Published: (2023-03-01)

Survival Benefit of Adjuvant Treatment with Huaier Granules Plus Lenvatinib in Hepatocellular Carcinoma Patients with Tumors Greater Than 5 cm After Radical Hepatectomy
by: Liu C, et al.
Published: (2025-07-01)

Regulation of lymphoma in vitro by CLP36 through the PI3K/AKT/CREB signaling pathway
by: Chao Lv, et al.
Published: (2024-12-01)

Non-Immune-Mediated, p27-Associated, Growth Inhibition of Glioblastoma by Class-II-Transactivator (CIITA)
by: A Katherine Tan, et al.
Published: (2024-11-01)

Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC
by: Zhengtao Hong, et al.
Published: (2025-02-01)

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
by: Shimpei Yamashita, et al.
Published: (2025-05-01)

Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of OATF against kidney stones
by: Sisi Dai, et al.
Published: (2025-05-01)

Recurrent Drug‐Induced Pneumothorax Associated With Lenvatinib: A Case Report
by: Ryo Torii, et al.
Published: (2025-05-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
by: Nazia Chaudhary, et al.
Published: (2025-02-01)

Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma
by: Lichang Huang, et al.
Published: (2025-05-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

Lenvatinib‐resistant hepatocellular carcinoma promotes malignant potential of tumor‐associated macrophages via exosomal miR‐301a‐3p
by: Yuhei Waki, et al.
Published: (2024-11-01)